Review Article
Efficacy and Safety of Acotiamide for the Treatment of Functional Dyspepsia: Systematic Review and Meta-Analysis
Table 1
Main characteristics of eligible studies.
| | Author, year | Location,
and number of centers | Publication
type | Diagnostic criteria | Number of patients | Dose of
acotiamide | Duration of
treatment | Jadad
score |
| Kusunoki et al.
2012 [11] | Japan, 1 site | Full text | Rome II criteria | 42 | 100 mg, tid | 14–18 d | 4 | Matsueda et al.
2010 (A) [16] | Japan, 33 sites | Full text | Rome II criteria | 323 | 100 mg
or 300 mg, tid | 4 w | 5 | Matsueda et al.
2010 (B) [16] | Japan, 46 sites | Full text | Rome II criteria | 462 | 50 mg, 100 mg
or 300 mg, tid | 4 w | 5 | Tack et al.
2009 [17] | Europe, 8 sites | Full text | Rome II criteria | 71 | 50 mg, 100 mg
or 300 mg, tid | 3 w | 4 | Talley et al.
2008 [18] | USA, 59 sites | Meeting
abstract | Rome II criteria | 416 | 300 mg, 600 mg
or 900 mg, tid | 12 w | 3 | Matsueda et al.
2005 [24] | Japan, NR | Meeting
abstract | Patients with FD symptoms and negative endoscopy | 127 | 50 mg, 100 mg
or 300 mg, tid | 4 w | 2 | Matsueda et al.
2012 [25] | Japan, 67 sites | Full text | Rome III criteria | 897 | 100 mg, tid | 4 w | 5 |
|
|
FD, functional dyspepsia; NR, not reported; RCT, randomized controlled trial; and tid, three times daily.
|
